Our findings indicated that MGMT promoter methylation was significantly correlated with pathological types, and it was significantly lower in serous carcinoma than in nonserous carcinoma (OR = 0.29, p = .001), which suggested that MGMT promoter methylation had a decreased the risk of serous ovarian cancer. Here, MGMT is linked to serous adenocarcinoma.